Nutra Pharma Corp.
Bringing Healthcare Solutions to the World
 
Newsroom
Recent News
Archives
E-Alerts
Press Kit
Drug Development
R&D Pipeline
Nutra Pharma is developing an innovative pipeline of biopharmaceutical products
E-Alerts
Signup to receive news and announcements from Nutra Pharma:
First Name:
Last Name:
Email:
Infinite Menus, Copyright 2006, OpenCube Inc. All Rights Reserved.

Newsroom

Nutra Pharma Announces Breakthrough with Rapid Tuberculosis Test Kit Technology
May 31, 2007

Nutra Pharma Corp, a biotechnology company that is developing drugs for HIV and Multiple Sclerosis has today announced that its medical devices division, Designer Diagnostics, has developed a rapid diagnostic test kit for Tuberculoses and will be conducting clinical trials at National Jewish Hospital in Denver, Colorado.

“With the recent scare out there of XDR-TB and MDR-TB, we believe that our test kit technology will help contribute to limiting the spread of the Tuberculosis around the world” explained Rik J Deitsch, Chairman of Nutra Pharma Corp. “We are working closely with world renowned researchers, Dr. Charles Daley and Dr. Leonid Heifets, at National Jewish Hospital to complete our clinical trials and our third-party validation,” he added.

Recently, a US passenger flying on transatlantic flights to and from Europe was diagnosed with a contagious form of XDR-Tuberculosis. This has caused a need for a rapid diagnostic testing of all the passengers and crew onboard those flights. Today, the infected passenger was transferred to National Jewish Hospital, as it is the leading research and treatment hospital for Tuberculosis.

“Over 14 million people are diagnosed with Tuberculosis around the world and 2 million patients die each year from the infectious disease,” commented Neil Roth, President of Designer Diagnostics, Inc. “Current testing can take up to 8-10 weeks for results, where as the Designer Diagnostic test kits have shown results in as little as 8-10 days. Once our test kits complete third party validation at National Jewish Hospital, we believe that our test kits will help save patient lives,” he concluded.

SEC Disclaimer

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The development of the tuberculosis test kit technology should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.


 
Quick Nav
Nyloxin // Chronic Pain Relief
Read about Jeff Gottfurcht, the first rheumatoid arthritis sufferer to conquer Everest, in Musculoskeletal Health a special section of the Washington Post.
 

 

 
Recent News
 
June 21, 2017
Nutra Pharma Announcing Launch of Luxury Feet


June 07, 2017
Nutra Pharma Featured on Univision's Spanish-Language News Show: Primer Impacto


May 31, 2017
Nutra Pharma Announces Collaboration with the University of Maryland Bioprocess Scale-Up Facility in Preparation of Material for Phase II Studies


 
 
Announcements
Click here to view a Letter to Shareholders from the Company's CEO, Rik J Deitsch.
 
 
Facebook   Twitter
 
NPC
Privacy Policy Code of Ethics